Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1
While immune checkpoint inhibitors are disrupting the management of patients with cancer, anecdotal occurrences of rapid progression (i.e., hyperprogressive disease or HPD) under these agents have been described, suggesting potentially deleterious effects of these drugs. ...Leggi tutto